Persistent Bacteremia Due to Methicillin-resistant Staphylococcus Aureus Infection is Associated with Agr Dysfunction and Low-level in Vitro Resistance to Thrombin-induced Platelet Microbicidal Protein
Overview
Authors
Affiliations
Background: The causes of persistent bacteremia (PB) due to methicillin-resistant Staphylococcus aureus (MRSA) are poorly understood. This investigation examined potential associations between PB with key clinical features and several in vitro bacterial genotypic and phenotypic characteristics, in isolates from 1 institution.
Methods: Pulsed-field gel electrophoresis (PFGE) relatedness, thrombin-induced platelet microbicidal protein (tPMP)-susceptibility phenotype, accessory gene regulator (agr) genotype and functionality (via delta-lysin production), and autolysis phenotypes were assessed in MRSA isolates from the bloodstream of 21 prospectively identified patients with PB (blood cultures positive after > or =7 days of therapy) and of 18 patients with resolving bacteremia (RB) (sterile blood cultures within the first 2-4 days of therapy) due to MRSA.
Results: The 2 groups had comparable baseline characteristics but differed in their clinical courses (e.g., endocarditis was more frequent in patients with PB than in those with RB [43% vs. 0%, respectively; P=.0016]); isolates from patients with PB exhibited higher rates of (1) survival in vitro after exposure to tPMP (22.4+/-14.8% vs. 11.6+/-6.5%, respectively; P=.005); (2) defective delta-lysin production (71.4% vs. 38.9%, respectively; P=.057); (3) non-agr genotype II profile (100% vs. 77.8%, respectively; P=.037); and (4) overrepresentation of a specific PFGE genotype (85.7% vs. 44.4%, respectively; P=.015).
Conclusions: Isolates from patients with PB differed from those in patients with RB, in several in vitro characteristics. Further studies will be necessary to define how these factors might affect clinical outcome.
Prophage ϕSA169 Enhances Vancomycin Persistence in Methicillin-Resistant (MRSA).
Li Y, Berti A, Abdelhady W, Xiong Y Antibiotics (Basel). 2025; 14(2).
PMID: 40001434 PMC: 11852059. DOI: 10.3390/antibiotics14020191.
Bergersen K, Zheng Y, Rossetti M, Ruffin F, Pickering H, Parmar R BMC Infect Dis. 2025; 25(1):231.
PMID: 39966757 PMC: 11834594. DOI: 10.1186/s12879-025-10620-3.
: Current perspectives on molecular pathogenesis and virulence.
Girma A Cell Surf. 2025; 13:100137.
PMID: 39758277 PMC: 11699754. DOI: 10.1016/j.tcsw.2024.100137.
Yang E, Cho Y, Kim E, Chang E, Bae S, Jung J Sci Rep. 2024; 14(1):15472.
PMID: 38969796 PMC: 11226624. DOI: 10.1038/s41598-024-66520-0.
Parmar R, Pickering H, Ahn R, Rossetti M, Gjertson D, Ruffin F Front Immunol. 2024; 15:1373553.
PMID: 38846955 PMC: 11153731. DOI: 10.3389/fimmu.2024.1373553.